1/7/2008 8:30:35 AM
MONTREAL--(BUSINESS WIRE)--Genizon BioSciences today announced the closing of its Series E financing in the amount of CAD$31 million. The lead investor is BTF B.V. of Haarlem, The Netherlands, a venture capital fund focused on late stage biotechnology companies. Several other existing investors also participated. The Company’s funding since its founding in 1999 totals over $130 million.
comments powered by